Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial

In people at high vascular risk, telmisartan's effects on major renal outcomes are similar to ramipril, and although combination therapy reduces proteinuria to a greater extent than monotherapy, overall it worsens major renal outcome.

Abstract

In people at high vascular risk, telmisartan's effects on major renal outcomes are similar to ramipril. Although combination therapy reduces proteinuria to a greater extent than monotherapy, overall it worsens major renal outcomes.